DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the WINDLAS BIOTECH LIMITED (WINDLAS) share price today?

WINDLAS BIOTECH LIMITED (WINDLAS) is trading at ₹844.25 on the NSE, down 0.71% on the day. Source: DocStoX.

What is the PE ratio of WINDLAS BIOTECH LIMITED?

WINDLAS BIOTECH LIMITED has a price-to-earnings (PE) ratio of 29.2 in the Healthcare sector.

What is the market capitalisation of WINDLAS BIOTECH LIMITED?

WINDLAS BIOTECH LIMITED has a market capitalisation of approximately ₹1,780 crore.

WINDLAS BIOTECH LIMITED

WINDLAS·NSE·Healthcare

₹844.25▼ -6.00 (-0.71%)

Healthcare · Pharmaceuticals

Revenue under pressure recently

Day₹833.25

₹854.75

52W₹697

₹109837%

Open

₹850.25

High

₹854.75

Low

₹833.25

Prev Close

₹850.25

Volume

49.0K

VWAP

₹842.48

Snapshot

Key fundamentals

Market Cap

₹1,780 Cr

P/E Ratio

29.17Fair

P/B Ratio

2.93

EPS

₹28.94

Book Value

₹281.35

ROE

11.44%Average

ROCE

17.00%Decent

Dividend Yield

0.76%

Debt / Equity

0.06Low

Face Value

₹5.00

52W High

₹1097.90

52W Low

₹697.40

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

None moatHigh uncertainty

Fair value estimate

₹313

▼ 62.9%downside

Trading at ₹844 — 63% above our estimate

BearFair valueBull

₹266₹313₹428

/100

Business quality — Watch the fundamentals

Growth 0Profitability 33Efficiency 31Valuation 75

Plain English

Our view

Revenue under pressure recently
Virtually debt-free balance sheet
Revenue has been shrinking

Strengths

Virtually debt-free balance sheet
Promoters hold a controlling stake

Risks

Revenue has been shrinking

How we got there

Fair value methods

Residual income

11% ROE fading to 12% over ~3 yrs, on ₹281 book

₹281

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹428

Analyst target

No analyst coverage

—

Blended fair value₹313

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Promoters hold a controlling stake

Bear case

Revenue has been shrinking

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

29.2Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

11.4%Average

Above 15% is considered healthy for Indian equities

ROCE

17.0%Decent

Above 18% means capital is working hard

Debt/Eq

0.06Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹1,780 Cr

P/B

2.93

EPS

₹28.94

Div Yield

0.76%

What changed

Recent changes

Domestic institutions+3.8% stake last quarter

What matters

News impact

Overview

Valuation

Reasonable

P/E 29.2×

Growth

Strong

+21% rev CAGR

Profitability

Modest

11.4% ROE

Financial health

Rock solid

D/E 0.06

Momentum

N/A

No technicals

Today

Trading activity

Delivery %49.1%

Turnover₹412.75L Cr

Trades5,217

VWAP₹842.48

Face value₹5.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+20.8%

+16.1%

10Y

+12.7%

Profit

+15.6%

+67.8%

10Y

+29.5%

EPS

—

10Y

—

Profile

Pros

Company is almost debt free.
Company has been maintaining a healthy dividend payout of 19.8%
Promoter holding has increased by 1.32% over last quarter.
Company's working capital requirements have reduced from 21.4 days to 14.4 days

Watch-outs

Cons

Company has a low return on equity of 12.8% over last 3 years.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 May 2026

Domestic institutions added 3.79 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

63%

Promoter

Promoters

63.3%0.00

Public

21.1%-8.19

FII / FPI

1.0%0.00

DII

10.2%+3.79

Others

4.4%

Total shareholders

46,084

Quarterly trend

Ownership over time

Q1 FY27

Promoter63.31%

FII0.99%

DII10.20%

Public21.10%

Others4.40%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions